C. Lu - Concepedia

Author

C. Lu

AstraZeneca (United States)ORCID

Also Known As

C Lu, C. Lu, Changhai Lu, Chang‐Hai Lu, Chanyi Lu, Chuang Lu

Publications

455

Citations

H-Index

Concepts

All Affiliations

AstraZeneca (United States)Dana-Farber Cancer Institute

About

C. Lu is an author at AstraZeneca (United States) specializing in medicine, pharmacology, and health sciences.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	272
2	Health Sciences	2	2	202
3	Biochemistry	1	1	192
4	Biostatistics	1	1	29
5	Immunology	1	1	10

C. Lu

Publications

334

Citations

H-Index

Page 1

	Year	Citations
Effects of organic solvents on the activities of cytochrome P450 isoforms, UDP-dependent glucuronyl transferase, and phenol sulfotransferase in human hepatocytes. Judy D. Easterbrook, C. Lu, Y Sakai, PubMed Toxicological MechanismOxidative StressMolecular PharmacologyMedicinal ChemistryOrganic Solvent	2001	192
A randomized, placebo-controlled phase II trial of ZD6474 plus docetaxel, in patients with NSCLC John V. Heymach, B. E. Johnson, Jacqui Rowbottom, Journal of Clinical Oncology OncologyClinical TherapeuticZd6474 300Tumor GrowthPharmacology	2005	41
Ultra-sensitive pH responsive hydrogels with injectable and self-healing performance for controlled drug delivery Yang Yu, Yili Zhao, Yujiao Zou, International Journal of Pharmaceutics X	2025	32
Physiologically based and population PK modeling in optimizing drug development: A predict–learn–confirm analysis Ajit Suri, Sunny Chapel, C. Lu, Clinical Pharmacology & Therapeutics PharmacotherapyPhysiologically-based Pharmacokinetic ModelingPharmacokineticsPharmacodynamic ModelingBiostatistics	2015	29
ZD6474, a novel antiangiogenic agent, in combination with docetaxel in patients with NSCLC: Results of the run-in phase of a two-part, randomized phase II study John V. Heymach, Runyu Dong, Isaiah W. Dimery, Journal of Clinical Oncology	2004	20
A multicenter, double-blind, placebo-controlled randomized phase II trial of gemcitabine/cisplatin (GC) plus bevacizumab (B) or placebo in patients (pts) with malignant mesothelioma (MM) Hedy L. Kindler, T. Karrison, C. Lu, Journal of Clinical Oncology ImmunologyHigh VegfPathologyImmunotherapeuticsMm Pts	2005	10
Recent advances in late‐stage selective deuteration for drug development Xuan Wang, Yun‐Xia Luo, Mao‐Chen Liu, Applied Organometallic Chemistry	2024	10

Page 1